361 Capital’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
HM
N
GPP
361 Capital's ACAD Position: Q1 2020 in Review
361 Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 29,686 shares — an estimated $1.27M sold.
361 Capital first reported a position in ACAD in Q3 2019 and held it in 2 quarters. The position peaked at $2.25M in Q3 2019. 246 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.
- 361 Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- 361 Capital sold 29,686 Acadia Pharmaceuticals shares in Q1 2020, an estimated $1.27M.
- 361 Capital first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 2 quarters.
- 361 Capital's Acadia Pharmaceuticals position peaked at $2.25M in Q3 2019.
- 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.
Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.